Answers are grounded in this paper and cite their sources.
This article examines the relationship between Helicobacter pylori infection and Non-Alcoholic Fatty Liver Disease (NAFLD). The global prevalence of NAFLD already accounts for 30.05% of the adult population, with prevalence varying across different regions of the world. Experts predict a further increase to over 55% by 2040. NAFLD is considered a multifactorial disorder, the pathogenesis of which involves concurrent processes, such as genetic and environmental factors, insulin resistance, impaired autophagy, lipotoxicity, inflammation, and microbiota imbalance. Evidence supporting the link between the gastrointestinal microbiota and the induction and progression of NAFLD is continually growing. H. pylori is a key etiologic factor in chronic gastritis, peptic ulcer disease, gastric cancer, and MALT lymphoma. H. pylori infection can disrupt a number of biological processes and influence the development and severity of extragastric pathology, including metabolic syndrome, diabetes mellitus, cardiovascular, respiratory, gastroenterological, hematological, and a number of other diseases. H. pylori induces a cascade of interrelated processes associated, either directly or indirectly through comorbid conditions, with the development and progression of NAFLD. Eradication of the infection in affected patients has a positive long-term pathogenetic effect on the course of NAFLD. Meanwhile, the implementation of four-component eradication regimens may be associated with additional challenges in patients with NAFLD. Increasing the effectiveness of eradication therapy and preventing worsening dysbiosis and the development of antibiotic resistance is possible by incorporating a medication containing butyric acid – a microbial metabolite with proven biological activity in the human body – and inulin, a substrate for its production by the body’s own microbiota. This drug demonstrates anti-inflammatory, immunoregulatory, adipose tissue-reducing, hypoglycemic, and lipid-lowering effects in NAFLD, supporting its rationale for use as part of combination therapy with ursodeoxycholic acid. Furthermore, continued use of ursodeoxycholic acid, a disease-modifying drug for NAFLD, during the eradication period will reduce the risk of drug-induced liver injury, which is highly associated with NAFLD and the use of antibiotics in the eradication regimen.
No takes yet. Share an insight, caveat, or question.
Elena V. Onuchina (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: